-
ALZHEIMER’S DRUG DISCOVERY FOUNDATION’S DIAGNOSTICS ACCELERATOR (DXA) Invests $1.4M in ViewMind’s technology.
28 Jan 2025 11:30 GMT
… impact of treatment would be very impactful for drug development and … research in academia and the biotech industry. The ADDF… 's PET scan (Amyvid®) and blood test (PrecivityAD®) … ;s drug discovery programs, biomarker programs and clinical trials in …
-
New Investment From The Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator (Dxa) Leads Efforts To Develop Standardization Materials For Leading Diagnostic Biomarker
14 Nov 2024 23:38 GMT
… medicine approach, representing the future of Alzheimer's treatment. … research in academia and the biotech industry. The ADDF… 's PET scan (Amyvid®) and blood test (PrecivityAD®) … ;s drug discovery programs, biomarker programs and clinical trials in …
-
GLX Analytix Announces Strategic Investment from Labcorp Venture Fund and Alzheimer’s Drug Discovery Foundation (ADDF)
29 Oct 2024 14:00 GMT
… services that helps doctors, hospitals, pharmaceutical companies, researchers, … in academia and the biotech industry. The ADDF … drug discovery programs, biomarker programs and clinical trials in … of more targeted treatments.
Maital Rasmussen
Chief …
-
Human medicines European public assessment report (EPAR): Amyvid, florbetapir (18F), Date of authorisation: 14/01/2013, Revision: 15, Status: Authorised
21 Oct 2024 15:13 GMT
The active substance in Amyvid, florbetapir (18F), is a radiopharmaceutical … on the PET scan, enabling doctors to know whether or not … elderly people with no symptoms. Doctors will therefore need to use …
-
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests
25 Sep 2024 18:36 GMT
… medicine—the holy grail of Alzheimer’s treatment.
ABOUT THE ALZHEIMER’S DRUG … ’s PET scan (Amyvid®) and blood test … includes landmark treatment and prevention trials involving disease- … with multi-national pharmaceutical and biotech companies, leading …
-
GE Healthcare wins FDA clearance for Alzheimer’s imaging software
20 Sep 2024 20:17 GMT
… approved Alzheimer's drugs, to standardize amyloid imaging … and evaluate their response to treatment. However, different centers have … , the Centers for Medicare and Medicaid Services changed its policy … as are Lilly’s Amyvid and Life Molecular Imaging’ …
-
ALZHEIMER'S DRUG DISCOVERY FOUNDATION (ADDF) STATEMENT ON FDA'S TRADITIONAL APPROVAL OF KISUNLA (DONANEMAB)
03 Jul 2024 03:53 GMT
… FDA approval of the monoclonal antibody donanemab (Kisunla) for the treatment … combination therapy and precision medicine, like within cancer care … The donanemab trial reaffirms the value of drug and biomarker … in academia and the biotech industry. The ADDF…
-
FDA Advisory Committee Supports Donanemab in Alzheimer’s Disease
11 Jun 2024 17:56 GMT
… the FDA’s Peripheral and Central Nervous System Drugs Advisory … department of Pathology Stanford Medicine Endowed Professor Stanford University … progression. The trial used the Amyvid and Tauvid PET …
Among all patients, treatment with donanemab reduced amyloid …
-
ALZHEIMER's DRUG DISCOVERY FOUNDATION's (ADDF) STATEMENT ON FDA ADVISORY COMMITTEE's ENDORSEMENT OF DONANEMAB
11 Jun 2024 04:10 GMT
… medicine approach will be needed to guide the next generation of treatments … trial for a neuroprotective drug now ready for phase 2b trials.
Diversity in the drug … in academia and the biotech industry. The ADDF… 39;s PET scan (Amyvid®) and blood test (PrecivityAD®) …
-
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
20 May 2024 12:30 GMT
… a planned Phase 2 trial in FTD.
“Inflammation … 's PET scan (Amyvid®) and blood test (PrecivityAD®) … ;s drug discovery programs, biomarker programs and clinical trials in … a clinical-stage biotechnology company developing proprietary treatments focused on …
About
© 1995-2025